Loading organizations...
MedaSystems provides a cloud-based software platform for pharmaceutical companies to manage global expanded and managed access programs for investigational medicines. This GxP-compliant system streamlines the complex process of requesting, approving, and distributing pre-approval therapies, enhancing collaboration with healthcare providers, ensuring regulatory adherence, and capturing essential real-world data.
MedaSystems was co-founded by Brian Irwin, its CEO, and Matthew Rosen, the EVP & Director. Irwin's extensive background as an operator and entrepreneur in healthcare underpinned the company's inception. Their insight addressed the significant administrative complexities faced by life science companies in navigating crucial pre-approval drug access pathways.
The company's clientele includes enterprise pharmaceutical companies, biotech firms, and Contract Research Organizations (CROs). MedaSystems envisions a world where patients and healthcare providers can easily access investigational medicines, free from administrative burden. Their mission empowers the pharmaceutical industry to achieve better patient care and outcomes through simplified, patient-centric collaboration.
MedaSystems has raised $2.0M across 1 funding round.
MedaSystems has raised $2.0M in total across 1 funding round.
MedaSystems is a Silicon Valley-based technology company founded in 2021 that builds a cloud-based software platform to automate workflows for managing pre-approval access programs, such as Expanded Access and Post-Trial Access, for experimental therapies.[1][2][4] The platform serves pharmaceutical and biotech companies, enabling faster approval decisions, real-world data capture, collaboration with healthcare providers (HCPs), and regulatory compliance, ultimately streamlining patient access to investigational medicines and improving outcomes.[1][2][3] It addresses inefficiencies in manual processes like spreadsheets, which hinder responses to physician requests, and is used by companies across the US and Europe, as well as major academic institutions.[1][2]
Growth momentum stems from strong investor backing, including Young Sohn (Veeva Systems founder), Nina Capital, and Debiopharm Innovation Fund, reflecting validation in health-tech.[1] Client success stories highlight reduced "fire drills" in handling inquiries, with features like task management and unified views driving adoption among life sciences firms processing thousands of requests annually.[2]
MedaSystems was founded in 2021 in Silicon Valley by a group of tech visionaries with backgrounds in biopharma and software, including founders experienced in developing solid tumor cancer therapies like those for glioblastoma.[1] The idea emerged during a phase 2 clinical trial when promising results prompted physician requests for FDA-expanded access, but manual tracking via spreadsheets proved inefficient—this pain point was recognized as widespread across biotech startups and large pharma companies handling thousands of such requests yearly.[1]
Determined to solve it, the team built their platform, drawing from thousands of hours collaborating with global pre-approval access experts.[1] Early traction came from addressing real-world bottlenecks in patient data collection and HCP interactions, leading to trust from pharma clients and academic institutions.[1][2]
MedaSystems stands out in the expanded access software market through its configurable, compliant platform tailored for life sciences. Key features include:
This developer-friendly, scalable design reduces friction compared to legacy manual methods.[1][3]
MedaSystems rides the trend of digital transformation in biopharma, where demand for investigational therapies surges amid faster drug development cycles and FDA emphasis on expanded access programs.[1][4] Timing is ideal as post-pandemic regulatory shifts and real-world evidence (RWE) requirements push pharma toward automated, data-rich platforms—MedaSystems captures RWE while complying with global standards, favoring it amid manual process bottlenecks.[1][2][3]
Market forces like rising clinical trial exclusions and physician advocacy amplify its role, influencing the ecosystem by enabling equitable access regardless of patient resources and fostering biopharma-HCP collaboration.[1][2] As health-tech funding grows (e.g., via backers like Nina Capital), it sets a standard for patient-centric software, competing with but surpassing generalists in pre-approval specificity.[5]
MedaSystems is poised for expansion with AI enhancements, deeper integrations, and global scaling, potentially capturing more of the fragmented expanded access market as RWE becomes regulatory gold.[3] Trends like AI in compliance, unified health data platforms, and personalized medicine will propel it, evolving its influence from workflow tool to indispensable RWE hub for pharma pipelines.[1][2]
Backing from proven investors signals runway for product evolution, tying back to its origin: transforming trial-era frustrations into lifesaving efficiency for patients worldwide.[1]
MedaSystems has raised $2.0M across 1 funding round. Most recently, it raised $2.0M Seed in March 2022.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Mar 1, 2022 | $2M Seed | Nina Capital | AME Cloud Ventures, Hardware Club, IST Cube | Announced |
MedaSystems has raised $2.0M in total across 1 funding round.
MedaSystems's investors include Nina Capital, AME Cloud Ventures, Hardware Club, IST cube.
